Dynavax Technologies Corporation (NASDAQ: DVAX) Stock Competitors & Peer Comparison
See DVAX's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for DVAX and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| DVAX | $15.50 | +0.00% | 1.8B | -41.89 | -$0.37 | N/A |
| TAK | $17.41 | -0.43% | 55.4B | 12.52 | $1.39 | +3.62% |
| HLN | $9.78 | -1.56% | 43.2B | 18.28 | $0.54 | +1.80% |
| TEVA | $37.02 | +1.48% | 42.8B | 12.54 | $2.93 | N/A |
| VTRS | $16.34 | +0.37% | 18.7B | 6.39 | $2.52 | +2.98% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| ELAN | $22.52 | -0.92% | 11.1B | 20.91 | $1.06 | N/A |
| RDY | $12.40 | -0.40% | 10.3B | 20.30 | $0.61 | +0.67% |
| LNTH | $100.96 | +0.28% | 6.6B | 16.93 | $5.95 | N/A |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
DVAX vs TAK Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, TAK has a market cap of 55.4B. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while TAK trades at $17.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas TAK's P/E ratio is 12.52. In terms of profitability, DVAX's ROE is -0.10%, compared to TAK's ROE of +0.02%. Regarding short-term risk, DVAX is less volatile compared to TAK. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check TAK's competition here
Haleon plc (NYSE: HLN)
DVAX vs HLN Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, HLN has a market cap of 43.2B. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while HLN trades at $9.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas HLN's P/E ratio is 18.28. In terms of profitability, DVAX's ROE is -0.10%, compared to HLN's ROE of +0.17%. Regarding short-term risk, DVAX is less volatile compared to HLN. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check HLN's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
DVAX vs TEVA Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, TEVA has a market cap of 42.8B. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while TEVA trades at $37.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas TEVA's P/E ratio is 12.54. In terms of profitability, DVAX's ROE is -0.10%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, DVAX is less volatile compared to TEVA. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check TEVA's competition here
Viatris Inc. (NASDAQ: VTRS)
DVAX vs VTRS Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, VTRS has a market cap of 18.7B. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while VTRS trades at $16.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas VTRS's P/E ratio is 6.39. In terms of profitability, DVAX's ROE is -0.10%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, DVAX is less volatile compared to VTRS. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
DVAX vs ITCI Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas ITCI's P/E ratio is -180.64. In terms of profitability, DVAX's ROE is -0.10%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, DVAX is similarly volatile compared to ITCI. This indicates similar risk in terms of short-term price fluctuations for DVAX.Check ITCI's competition here
Catalent, Inc. (NYSE: CTLT)
DVAX vs CTLT Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas CTLT's P/E ratio is -27.84. In terms of profitability, DVAX's ROE is -0.10%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, DVAX is less volatile compared to CTLT. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check CTLT's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
DVAX vs ELAN Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, ELAN has a market cap of 11.1B. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while ELAN trades at $22.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas ELAN's P/E ratio is 20.91. In terms of profitability, DVAX's ROE is -0.10%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, DVAX is less volatile compared to ELAN. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check ELAN's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
DVAX vs RDY Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, RDY has a market cap of 10.3B. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while RDY trades at $12.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas RDY's P/E ratio is 20.30. In terms of profitability, DVAX's ROE is -0.10%, compared to RDY's ROE of +0.09%. Regarding short-term risk, DVAX is less volatile compared to RDY. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check RDY's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
DVAX vs LNTH Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, LNTH has a market cap of 6.6B. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while LNTH trades at $100.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas LNTH's P/E ratio is 16.93. In terms of profitability, DVAX's ROE is -0.10%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, DVAX is less volatile compared to LNTH. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check LNTH's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
DVAX vs AMRX Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, AMRX has a market cap of 5.6B. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while AMRX trades at $17.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas AMRX's P/E ratio is 19.62. In terms of profitability, DVAX's ROE is -0.10%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, DVAX is less volatile compared to AMRX. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check AMRX's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
DVAX vs INDV Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, INDV has a market cap of 4.8B. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while INDV trades at $38.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas INDV's P/E ratio is 10.61. In terms of profitability, DVAX's ROE is -0.10%, compared to INDV's ROE of -2.16%. Regarding short-term risk, DVAX is less volatile compared to INDV. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check INDV's competition here
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
DVAX vs SUPN Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, SUPN has a market cap of 2.8B. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while SUPN trades at $47.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas SUPN's P/E ratio is 15.64. In terms of profitability, DVAX's ROE is -0.10%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, DVAX is less volatile compared to SUPN. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check SUPN's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
DVAX vs RGC Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, RGC has a market cap of 2.5B. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while RGC trades at $5.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas RGC's P/E ratio is -356.34. In terms of profitability, DVAX's ROE is -0.10%, compared to RGC's ROE of -2.32%. Regarding short-term risk, DVAX is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check RGC's competition here
Bausch Health Companies Inc. (NYSE: BHC)
DVAX vs BHC Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, BHC has a market cap of 2.3B. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while BHC trades at $6.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas BHC's P/E ratio is 1.58. In terms of profitability, DVAX's ROE is -0.10%, compared to BHC's ROE of +0.89%. Regarding short-term risk, DVAX is less volatile compared to BHC. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check BHC's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
DVAX vs DCPH Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas DCPH's P/E ratio is -11.58. In terms of profitability, DVAX's ROE is -0.10%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, DVAX is less volatile compared to DCPH. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check DCPH's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
DVAX vs HCM Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, HCM has a market cap of 2.1B. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while HCM trades at $12.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas HCM's P/E ratio is 4.59. In terms of profitability, DVAX's ROE is -0.10%, compared to HCM's ROE of +0.01%. Regarding short-term risk, DVAX is less volatile compared to HCM. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check HCM's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
DVAX vs AVDL Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, DVAX's ROE is -0.10%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, DVAX is similarly volatile compared to AVDL. This indicates similar risk in terms of short-term price fluctuations for DVAX.Check AVDL's competition here
Embecta Corp. (NASDAQ: EMBCV)
DVAX vs EMBCV Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas EMBCV's P/E ratio is N/A. In terms of profitability, DVAX's ROE is -0.10%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, DVAX is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check EMBCV's competition here
Perrigo Company plc (NYSE: PRGO)
DVAX vs PRGO Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, PRGO has a market cap of 1.8B. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while PRGO trades at $12.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas PRGO's P/E ratio is 5.07. In terms of profitability, DVAX's ROE is -0.10%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, DVAX is less volatile compared to PRGO. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check PRGO's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
DVAX vs ANIP Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, ANIP has a market cap of 1.7B. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while ANIP trades at $75.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas ANIP's P/E ratio is 9.14. In terms of profitability, DVAX's ROE is -0.10%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, DVAX is less volatile compared to ANIP. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check ANIP's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
DVAX vs TARO Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas TARO's P/E ratio is 30.05. In terms of profitability, DVAX's ROE is -0.10%, compared to TARO's ROE of +0.03%. Regarding short-term risk, DVAX is less volatile compared to TARO. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check TARO's competition here
Harrow Health, Inc. (NASDAQ: HROW)
DVAX vs HROW Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, HROW has a market cap of 1.5B. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while HROW trades at $40.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas HROW's P/E ratio is 437.33. In terms of profitability, DVAX's ROE is -0.10%, compared to HROW's ROE of -1.04%. Regarding short-term risk, DVAX is less volatile compared to HROW. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check HROW's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
DVAX vs PAHC Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, PAHC has a market cap of 1.4B. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while PAHC trades at $34.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas PAHC's P/E ratio is 11.54. In terms of profitability, DVAX's ROE is -0.10%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, DVAX is less volatile compared to PAHC. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check PAHC's competition here
Alvotech (NASDAQ: ALVO)
DVAX vs ALVO Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, ALVO has a market cap of 1.4B. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while ALVO trades at $3.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas ALVO's P/E ratio is -11.79. In terms of profitability, DVAX's ROE is -0.10%, compared to ALVO's ROE of +0.35%. Regarding short-term risk, DVAX is less volatile compared to ALVO. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check ALVO's competition here
Cronos Group Inc. (NASDAQ: CRON)
DVAX vs CRON Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, CRON has a market cap of 1.2B. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while CRON trades at $3.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas CRON's P/E ratio is 30.10. In terms of profitability, DVAX's ROE is -0.10%, compared to CRON's ROE of +0.06%. Regarding short-term risk, DVAX is less volatile compared to CRON. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check CRON's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
DVAX vs ETON Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, ETON has a market cap of 1.1B. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while ETON trades at $42.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas ETON's P/E ratio is -594.00. In terms of profitability, DVAX's ROE is -0.10%, compared to ETON's ROE of -0.06%. Regarding short-term risk, DVAX is less volatile compared to ETON. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check ETON's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
DVAX vs PCRX Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, PCRX has a market cap of 932.2M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while PCRX trades at $23.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas PCRX's P/E ratio is 9.12. In terms of profitability, DVAX's ROE is -0.10%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, DVAX is less volatile compared to PCRX. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check PCRX's competition here
PetIQ, Inc. (NASDAQ: PETQ)
DVAX vs PETQ Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas PETQ's P/E ratio is 83.73. In terms of profitability, DVAX's ROE is -0.10%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, DVAX is less volatile compared to PETQ. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check PETQ's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
DVAX vs AMPH Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, AMPH has a market cap of 881M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while AMPH trades at $20.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas AMPH's P/E ratio is 6.82. In terms of profitability, DVAX's ROE is -0.10%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, DVAX is less volatile compared to AMPH. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check AMPH's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
DVAX vs COLL Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, COLL has a market cap of 842.6M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while COLL trades at $28.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas COLL's P/E ratio is 3.26. In terms of profitability, DVAX's ROE is -0.10%, compared to COLL's ROE of +0.16%. Regarding short-term risk, DVAX is less volatile compared to COLL. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check COLL's competition here
Evotec SE (NASDAQ: EVO)
DVAX vs EVO Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, EVO has a market cap of 778M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while EVO trades at $2.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas EVO's P/E ratio is -3.09. In terms of profitability, DVAX's ROE is -0.10%, compared to EVO's ROE of -0.24%. Regarding short-term risk, DVAX is less volatile compared to EVO. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check EVO's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
DVAX vs IRWD Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, IRWD has a market cap of 711.1M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while IRWD trades at $4.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas IRWD's P/E ratio is 5.54. In terms of profitability, DVAX's ROE is -0.10%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, DVAX is less volatile compared to IRWD. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check IRWD's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
DVAX vs BDSI Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas BDSI's P/E ratio is 6.82. In terms of profitability, DVAX's ROE is -0.10%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, DVAX is less volatile compared to BDSI. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check BDSI's competition here
Evolus, Inc. (NASDAQ: EOLS)
DVAX vs EOLS Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, EOLS has a market cap of 534.7M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while EOLS trades at $8.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas EOLS's P/E ratio is -25.71. In terms of profitability, DVAX's ROE is -0.10%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, DVAX is less volatile compared to EOLS. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check EOLS's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
DVAX vs AQST Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, AQST has a market cap of 530.7M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while AQST trades at $4.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas AQST's P/E ratio is -6.93. In terms of profitability, DVAX's ROE is -0.10%, compared to AQST's ROE of +2.44%. Regarding short-term risk, DVAX is less volatile compared to AQST. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check AQST's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
DVAX vs TLRY Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, TLRY has a market cap of 523.4M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while TLRY trades at $4.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas TLRY's P/E ratio is -4.32. In terms of profitability, DVAX's ROE is -0.10%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, DVAX is less volatile compared to TLRY. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check TLRY's competition here
Canopy Growth Corporation (NASDAQ: CGC)
DVAX vs CGC Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, CGC has a market cap of 432.7M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while CGC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas CGC's P/E ratio is -0.62. In terms of profitability, DVAX's ROE is -0.10%, compared to CGC's ROE of -0.33%. Regarding short-term risk, DVAX is less volatile compared to CGC. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check CGC's competition here
Kamada Ltd. (NASDAQ: KMDA)
DVAX vs KMDA Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, KMDA has a market cap of 396.9M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while KMDA trades at $7.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas KMDA's P/E ratio is 19.66. In terms of profitability, DVAX's ROE is -0.10%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, DVAX is less volatile compared to KMDA. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check KMDA's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
DVAX vs TKNO Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, TKNO has a market cap of 396.2M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while TKNO trades at $7.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas TKNO's P/E ratio is -23.84. In terms of profitability, DVAX's ROE is -0.10%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, DVAX is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check TKNO's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
DVAX vs ALIM Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas ALIM's P/E ratio is 5.28. In terms of profitability, DVAX's ROE is -0.10%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, DVAX is less volatile compared to ALIM. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check ALIM's competition here
Embecta Corp. (NASDAQ: EMBC)
DVAX vs EMBC Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, EMBC has a market cap of 281.8M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while EMBC trades at $5.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas EMBC's P/E ratio is 1.83. In terms of profitability, DVAX's ROE is -0.10%, compared to EMBC's ROE of -0.14%. Regarding short-term risk, DVAX is less volatile compared to EMBC. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check EMBC's competition here
Landec Corporation (NASDAQ: LNDC)
DVAX vs LNDC Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas LNDC's P/E ratio is -4.04. In terms of profitability, DVAX's ROE is -0.10%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, DVAX is less volatile compared to LNDC. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check LNDC's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
DVAX vs ACB Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, ACB has a market cap of 236.6M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while ACB trades at $3.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas ACB's P/E ratio is -7.80. In terms of profitability, DVAX's ROE is -0.10%, compared to ACB's ROE of -0.21%. Regarding short-term risk, DVAX is less volatile compared to ACB. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check ACB's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
DVAX vs ORGO Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, ORGO has a market cap of 232.9M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while ORGO trades at $1.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas ORGO's P/E ratio is 60.33. In terms of profitability, DVAX's ROE is -0.10%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, DVAX is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check ORGO's competition here
Shineco, Inc. (NASDAQ: TYHT)
DVAX vs TYHT Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas TYHT's P/E ratio is -1.61. In terms of profitability, DVAX's ROE is -0.10%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, DVAX is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check TYHT's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
DVAX vs SIGA Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, SIGA has a market cap of 205.8M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while SIGA trades at $2.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas SIGA's P/E ratio is 10.63. In terms of profitability, DVAX's ROE is -0.10%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, DVAX is less volatile compared to SIGA. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check SIGA's competition here
Organigram Global Inc. (NASDAQ: OGI)
DVAX vs OGI Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, OGI has a market cap of 181.6M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while OGI trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas OGI's P/E ratio is -4.96. In terms of profitability, DVAX's ROE is -0.10%, compared to OGI's ROE of -0.07%. Regarding short-term risk, DVAX is less volatile compared to OGI. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check OGI's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
DVAX vs LFCR Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, LFCR has a market cap of 178.9M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while LFCR trades at $4.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas LFCR's P/E ratio is -4.46. In terms of profitability, DVAX's ROE is -0.10%, compared to LFCR's ROE of -2.51%. Regarding short-term risk, DVAX is less volatile compared to LFCR. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check LFCR's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
DVAX vs REPH Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas REPH's P/E ratio is -8.04. In terms of profitability, DVAX's ROE is -0.10%, compared to REPH's ROE of -0.22%. Regarding short-term risk, DVAX is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check REPH's competition here
Journey Medical Corporation (NASDAQ: DERM)
DVAX vs DERM Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, DERM has a market cap of 177M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while DERM trades at $6.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas DERM's P/E ratio is -17.38. In terms of profitability, DVAX's ROE is -0.10%, compared to DERM's ROE of -0.36%. Regarding short-term risk, DVAX is less volatile compared to DERM. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check DERM's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
DVAX vs CRDL Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, CRDL has a market cap of 175.2M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while CRDL trades at $1.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas CRDL's P/E ratio is -5.41. In terms of profitability, DVAX's ROE is -0.10%, compared to CRDL's ROE of -2.29%. Regarding short-term risk, DVAX is less volatile compared to CRDL. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check CRDL's competition here
Theratechnologies Inc. (NASDAQ: THTX)
DVAX vs THTX Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas THTX's P/E ratio is -28.83. In terms of profitability, DVAX's ROE is -0.10%, compared to THTX's ROE of +0.17%. Regarding short-term risk, DVAX is less volatile compared to THTX. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check THTX's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
DVAX vs ASRT Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas ASRT's P/E ratio is -7.10. In terms of profitability, DVAX's ROE is -0.10%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, DVAX is less volatile compared to ASRT. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check ASRT's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
DVAX vs CPIX Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, CPIX has a market cap of 119.3M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while CPIX trades at $7.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas CPIX's P/E ratio is -19.90. In terms of profitability, DVAX's ROE is -0.10%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, DVAX is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check CPIX's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
DVAX vs SCTL Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas SCTL's P/E ratio is -7.86. In terms of profitability, DVAX's ROE is -0.10%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, DVAX is less volatile compared to SCTL. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check SCTL's competition here
BGM Group Ltd. (NASDAQ: BGM)
DVAX vs BGM Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, BGM has a market cap of 111.9M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while BGM trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas BGM's P/E ratio is -1.01. In terms of profitability, DVAX's ROE is -0.10%, compared to BGM's ROE of -0.07%. Regarding short-term risk, DVAX is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check BGM's competition here
Procaps Group S.A. (NASDAQ: PROC)
DVAX vs PROC Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas PROC's P/E ratio is 1.53. In terms of profitability, DVAX's ROE is -0.10%, compared to PROC's ROE of -2.22%. Regarding short-term risk, DVAX is similarly volatile compared to PROC. This indicates similar risk in terms of short-term price fluctuations for DVAX.Check PROC's competition here
OptiNose, Inc. (NASDAQ: OPTN)
DVAX vs OPTN Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas OPTN's P/E ratio is -4.42. In terms of profitability, DVAX's ROE is -0.10%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, DVAX is similarly volatile compared to OPTN. This indicates similar risk in terms of short-term price fluctuations for DVAX.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
DVAX vs ZOM Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas ZOM's P/E ratio is -1.62. In terms of profitability, DVAX's ROE is -0.10%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, DVAX is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check ZOM's competition here
Upexi, Inc. (NASDAQ: GRVI)
DVAX vs GRVI Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas GRVI's P/E ratio is 26.05. In terms of profitability, DVAX's ROE is -0.10%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, DVAX is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check GRVI's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
DVAX vs ZYBT Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, ZYBT has a market cap of 73.5M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while ZYBT trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas ZYBT's P/E ratio is -7.05. In terms of profitability, DVAX's ROE is -0.10%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, DVAX is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check ZYBT's competition here
Talphera, Inc. (NASDAQ: TLPH)
DVAX vs TLPH Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, TLPH has a market cap of 72.7M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while TLPH trades at $1.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas TLPH's P/E ratio is -4.52. In terms of profitability, DVAX's ROE is -0.10%, compared to TLPH's ROE of -0.93%. Regarding short-term risk, DVAX is less volatile compared to TLPH. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check TLPH's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
DVAX vs ZYNE Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, DVAX's ROE is -0.10%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, DVAX is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check ZYNE's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
DVAX vs SSIC Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas SSIC's P/E ratio is 11.93. In terms of profitability, DVAX's ROE is -0.10%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, DVAX is less volatile compared to SSIC. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check SSIC's competition here
The Valens Company Inc. (NASDAQ: VLNS)
DVAX vs VLNS Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas VLNS's P/E ratio is -1.03. In terms of profitability, DVAX's ROE is -0.10%, compared to VLNS's ROE of N/A. Regarding short-term risk, DVAX is less volatile compared to VLNS. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check VLNS's competition here
DURECT Corporation (NASDAQ: DRRX)
DVAX vs DRRX Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas DRRX's P/E ratio is -4.44. In terms of profitability, DVAX's ROE is -0.10%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, DVAX is similarly volatile compared to DRRX. This indicates similar risk in terms of short-term price fluctuations for DVAX.Check DRRX's competition here
InterCure Ltd. (NASDAQ: INCR)
DVAX vs INCR Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, INCR has a market cap of 57.1M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while INCR trades at $0.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas INCR's P/E ratio is -2.23. In terms of profitability, DVAX's ROE is -0.10%, compared to INCR's ROE of -0.09%. Regarding short-term risk, DVAX is less volatile compared to INCR. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check INCR's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
DVAX vs JUPW Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas JUPW's P/E ratio is -2.41. In terms of profitability, DVAX's ROE is -0.10%, compared to JUPW's ROE of -1.94%. Regarding short-term risk, DVAX is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check JUPW's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
DVAX vs CPHI Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, CPHI has a market cap of 44.6M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while CPHI trades at $1.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas CPHI's P/E ratio is -1.72. In terms of profitability, DVAX's ROE is -0.10%, compared to CPHI's ROE of -0.19%. Regarding short-term risk, DVAX is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check CPHI's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
DVAX vs QLI Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas QLI's P/E ratio is -4.92. In terms of profitability, DVAX's ROE is -0.10%, compared to QLI's ROE of -0.16%. Regarding short-term risk, DVAX is similarly volatile compared to QLI. This indicates similar risk in terms of short-term price fluctuations for DVAX.Check QLI's competition here
HEXO Corp. (NASDAQ: HEXO)
DVAX vs HEXO Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas HEXO's P/E ratio is -0.26. In terms of profitability, DVAX's ROE is -0.10%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, DVAX is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check HEXO's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
DVAX vs RMTI Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, RMTI has a market cap of 30.8M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while RMTI trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas RMTI's P/E ratio is -7.42. In terms of profitability, DVAX's ROE is -0.10%, compared to RMTI's ROE of -0.15%. Regarding short-term risk, DVAX is less volatile compared to RMTI. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check RMTI's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
DVAX vs AYTU Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, AYTU has a market cap of 25.3M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while AYTU trades at $2.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas AYTU's P/E ratio is -1.23. In terms of profitability, DVAX's ROE is -0.10%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, DVAX is less volatile compared to AYTU. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check AYTU's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
DVAX vs TXMD Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, TXMD has a market cap of 24.1M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while TXMD trades at $2.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas TXMD's P/E ratio is 105.96. In terms of profitability, DVAX's ROE is -0.10%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, DVAX is less volatile compared to TXMD. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check TXMD's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
DVAX vs CYTH Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas CYTH's P/E ratio is -0.80. In terms of profitability, DVAX's ROE is -0.10%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, DVAX is similarly volatile compared to CYTH. This indicates similar risk in terms of short-term price fluctuations for DVAX.Check CYTH's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
DVAX vs EVOK Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas EVOK's P/E ratio is -7.97. In terms of profitability, DVAX's ROE is -0.10%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, DVAX is similarly volatile compared to EVOK. This indicates similar risk in terms of short-term price fluctuations for DVAX.Check EVOK's competition here
Optimi Health Corp. (NASDAQ: OPTH)
DVAX vs OPTH Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, OPTH has a market cap of 15.3M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while OPTH trades at $4.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas OPTH's P/E ratio is -17.38. In terms of profitability, DVAX's ROE is -0.10%, compared to OPTH's ROE of -0.94%. Regarding short-term risk, DVAX is less volatile compared to OPTH. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check OPTH's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
DVAX vs ACRX Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas ACRX's P/E ratio is -0.31. In terms of profitability, DVAX's ROE is -0.10%, compared to ACRX's ROE of -0.93%. Regarding short-term risk, DVAX is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check ACRX's competition here
Biofrontera Inc. (NASDAQ: BFRIW)
DVAX vs BFRIW Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, BFRIW has a market cap of 13.3M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while BFRIW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas BFRIW's P/E ratio is -0.02. In terms of profitability, DVAX's ROE is -0.10%, compared to BFRIW's ROE of -4.77%. Regarding short-term risk, DVAX is less volatile compared to BFRIW. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check BFRIW's competition here
Cosmos Health Inc. (NASDAQ: COSM)
DVAX vs COSM Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, COSM has a market cap of 11.7M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while COSM trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas COSM's P/E ratio is -0.29. In terms of profitability, DVAX's ROE is -0.10%, compared to COSM's ROE of -0.96%. Regarding short-term risk, DVAX is less volatile compared to COSM. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check COSM's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
DVAX vs AGRX Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas AGRX's P/E ratio is -0.89. In terms of profitability, DVAX's ROE is -0.10%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, DVAX is less volatile compared to AGRX. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check AGRX's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
DVAX vs NLTX Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas NLTX's P/E ratio is -0.28. In terms of profitability, DVAX's ROE is -0.10%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, DVAX is less volatile compared to NLTX. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check NLTX's competition here
Lannett Company, Inc. (NYSE: LCI)
DVAX vs LCI Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas LCI's P/E ratio is -0.04. In terms of profitability, DVAX's ROE is -0.10%, compared to LCI's ROE of +1.66%. Regarding short-term risk, DVAX is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
DVAX vs ADMP Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas ADMP's P/E ratio is -0.08. In terms of profitability, DVAX's ROE is -0.10%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, DVAX is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check ADMP's competition here
cbdMD, Inc. (AMEX: YCBD)
DVAX vs YCBD Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, YCBD has a market cap of 6.3M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while YCBD trades at $0.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas YCBD's P/E ratio is -1.49. In terms of profitability, DVAX's ROE is -0.10%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, DVAX is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check YCBD's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
DVAX vs GELS Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, GELS has a market cap of 5.2M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while GELS trades at $0.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas GELS's P/E ratio is -1.14. In terms of profitability, DVAX's ROE is -0.10%, compared to GELS's ROE of -0.25%. Regarding short-term risk, DVAX is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check GELS's competition here
Mallinckrodt plc (AMEX: MNK)
DVAX vs MNK Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas MNK's P/E ratio is -0.44. In terms of profitability, DVAX's ROE is -0.10%, compared to MNK's ROE of -0.36%. Regarding short-term risk, DVAX is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check MNK's competition here
Flora Growth Corp. (NASDAQ: FLGC)
DVAX vs FLGC Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas FLGC's P/E ratio is -0.19. In terms of profitability, DVAX's ROE is -0.10%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, DVAX is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check FLGC's competition here
Universe Pharmaceuticals Inc. (NASDAQ: UPC)
DVAX vs UPC Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, UPC has a market cap of 3.8M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while UPC trades at $5.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas UPC's P/E ratio is -0.75. In terms of profitability, DVAX's ROE is -0.10%, compared to UPC's ROE of -0.03%. Regarding short-term risk, DVAX is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check UPC's competition here
Sunshine Biopharma, Inc. (NASDAQ: SBFM)
DVAX vs SBFM Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, SBFM has a market cap of 2.9M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while SBFM trades at $1.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas SBFM's P/E ratio is -0.20. In terms of profitability, DVAX's ROE is -0.10%, compared to SBFM's ROE of -0.26%. Regarding short-term risk, DVAX is less volatile compared to SBFM. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check SBFM's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
DVAX vs PLXP Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas PLXP's P/E ratio is -0.22. In terms of profitability, DVAX's ROE is -0.10%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, DVAX is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check PLXP's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
DVAX vs SHPH Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, SHPH has a market cap of 2.5M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while SHPH trades at $4.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas SHPH's P/E ratio is -0.20. In terms of profitability, DVAX's ROE is -0.10%, compared to SHPH's ROE of -4.08%. Regarding short-term risk, DVAX is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check SHPH's competition here
Athenex, Inc. (NASDAQ: ATNX)
DVAX vs ATNX Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas ATNX's P/E ratio is -0.02. In terms of profitability, DVAX's ROE is -0.10%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, DVAX is similarly volatile compared to ATNX. This indicates similar risk in terms of short-term price fluctuations for DVAX.Check ATNX's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
DVAX vs SNOA Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, SNOA has a market cap of 2.3M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while SNOA trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas SNOA's P/E ratio is -1.16. In terms of profitability, DVAX's ROE is -0.10%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, DVAX is less volatile compared to SNOA. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check SNOA's competition here
Procaps Group, S.A. (NASDAQ: PROCW)
DVAX vs PROCW Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, PROCW has a market cap of 2M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while PROCW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas PROCW's P/E ratio is N/A. In terms of profitability, DVAX's ROE is -0.10%, compared to PROCW's ROE of -2.22%. Regarding short-term risk, DVAX is similarly volatile compared to PROCW. This indicates similar risk in terms of short-term price fluctuations for DVAX.Check PROCW's competition here
RedHill Biopharma Ltd. (NASDAQ: RDHL)
DVAX vs RDHL Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, RDHL has a market cap of 1.9M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while RDHL trades at $0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas RDHL's P/E ratio is 0.12. In terms of profitability, DVAX's ROE is -0.10%, compared to RDHL's ROE of +57.40%. Regarding short-term risk, DVAX is less volatile compared to RDHL. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check RDHL's competition here
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC)
DVAX vs SXTC Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, SXTC has a market cap of 1.8M. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while SXTC trades at $3.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas SXTC's P/E ratio is 1.18. In terms of profitability, DVAX's ROE is -0.10%, compared to SXTC's ROE of -0.31%. Regarding short-term risk, DVAX is less volatile compared to SXTC. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check SXTC's competition here
cbdMD, Inc. (AMEX: YCBD-PA)
DVAX vs YCBD-PA Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, YCBD-PA has a market cap of 928.2K. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while YCBD-PA trades at $1.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas YCBD-PA's P/E ratio is -2.69. In terms of profitability, DVAX's ROE is -0.10%, compared to YCBD-PA's ROE of -0.34%. Regarding short-term risk, DVAX is less volatile compared to YCBD-PA. This indicates lower risk in terms of short-term price fluctuations for DVAX.Check YCBD-PA's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTHW)
DVAX vs CYTHW Comparison August 2026
Dynavax Technologies Corporation (NASDAQ: DVAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVAX stands at 1.8B. In comparison, CYTHW has a market cap of 928K. Regarding current trading prices, DVAX is priced at $15.50 on the NASDAQ, while CYTHW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVAX currently has a P/E ratio of -41.89, whereas CYTHW's P/E ratio is N/A. In terms of profitability, DVAX's ROE is -0.10%, compared to CYTHW's ROE of -7.30%. Regarding short-term risk, DVAX is similarly volatile compared to CYTHW. This indicates similar risk in terms of short-term price fluctuations for DVAX.Check CYTHW's competition here